Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://ncbi.nlm.nih.gov/pubmed/26283632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0721-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados